CSBR Champions Oncology, Inc. - Common Stock
NASDAQ · Life Sciences Tools & Services · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Sep 11, 2026CSBR Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
CSBR Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
| Ex-Datum | Split | Typ |
|---|---|---|
| 12. August 2015 | 1-for-12 | Umgekehrt |
Über Champions Oncology, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
TumorGrafts
Champions TumorGrafts maintain the microenvironment surrounding the tumor and have been shown to have high correlation to the patient’s tumor. Due to this close resemblance to the human tumor, TumorGrafts are highly predictive of treatment outcomes in patients. Studies have shown the mouse avatars predict clinical benefit in 80% of patients. Approximately 450 TumorGrafts have been established as of April 2014.
TumorGrafts are also being used as a pre-clinical research tool to improve clinical drug development. Compared to traditional xenograft models, TumorGrafts, have a greater degree of accuracy in predicting clinical effectiveness of oncology drugs and thus can decrease clinical risk for drug developers. Champions has formed partnerships with multiple drug developers, including Teva and Pfizer.
The process
When a cancer patient undergoes surgery or biopsy, a living sample of the tumor is obtained and implanted into the mouse, creating a mouse avatar. Once the TumorGraft has successfully grown, the tumor is then propagated in a second generation of mice and tested against a panel of cancer drugs and drug combinations to help identify more accurately which treatment regimen is likely to be most effective in a specific patient. In this way, various drugs are tested on a live sample of the actual patient's tumor, rather than on the patient. This reduces the likelihood of treatment with ineffective drugs and their associated side effects, and it increases the likelihood of finding a treatment that will work against the patient's tumor. For patients whose tumors have also undergone molecular testing, such as next-generation sequencing, the selection of potential drugs is further guided by any and all applicable results. In the event the cancer progresses or recurs, Champions also banks, or stores, each successful TumorGraft for potential future patient use.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | CSBR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -61.85-Jahres-Durchschnitt ≈23.5 | ≈23.5 | · | · | |
| P/S (TTM) | 1.15-Jahres-Durchschnitt ≈1.6 | ≈1.6 | 2.7 | Unterbewertet | |
| K/B (MRQ) | 17.75-Jahres-Durchschnitt ≈7.7 | ≈7.7 | 1.8 | Überbewertet | |
| Kurs / FCF (TTM) | -11.25-Jahres-Durchschnitt ≈14.8 | ≈14.8 | · | · | |
| Kurs / Cashflow (TTM) | -12.45-Jahres-Durchschnitt ≈3.4 | ≈3.4 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 19.05-Jahres-Durchschnitt ≈19.7 | ≈19.7 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | CSBR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -1.7%5-Jahres-Durchschnitt ≈-3.4% | ≈-3.4% | -108.0% | Spitzenklasse | |
| EBITDA-Marge (TTM) | 0.55%5-Jahres-Durchschnitt ≈-0.32% | ≈-0.32% | -108.0% | Spitzenklasse | |
| Vorgewinnmarge (TTM) | -1.5%5-Jahres-Durchschnitt ≈-3.3% | ≈-3.3% | -100.0% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | -1.9%5-Jahres-Durchschnitt ≈-3.4% | ≈-3.4% | -105.8% | Spitzenklasse | |
| ROA | -4.0%5-Jahres-Durchschnitt ≈-5.1% | ≈-5.1% | -26.0% | Spitzenklasse | |
| ROE | -30.5%5-Jahres-Durchschnitt ≈92.6% | ≈92.6% | -34.9% | Im Einklang | |
| ROIC | -36.6%5-Jahres-Durchschnitt ≈72.5% | ≈72.5% | -38.6% | Im Einklang |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | CSBR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 1.05-Jahres-Durchschnitt ≈0.9 | ≈0.9 | 2.9 | Geringe Liquidität | |
| Quick Ratio | 0.95-Jahres-Durchschnitt ≈0.8 | ≈0.8 | 1.4 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | CSBR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 4.4%5-Jahres-Durchschnitt ≈8.1% | ≈8.1% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 3.3%5-Jahres-Durchschnitt ≈8.5% | ≈8.5% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 7.7% | · | · | · | |
| EPS CAGR 3Y (EPS CAGR 3J) | 102.1% | · | · | · | |
| Net Income CAGR 3Y (Nettoergebnis CAGR 3J) | 104.7% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | CSBR | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 2.05-Jahres-Durchschnitt ≈1.7 | ≈1.7 | 0.4 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 4.95-Jahres-Durchschnitt ≈5.7 | ≈5.7 | 5.0 | Im Einklang | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$277.7K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 31. März 2027 | Sep 10, 2026 | $-0.03 | $-0.01 | -194.1% |
| 30. September 2026 | $-0.03 | $-0.01 | -194.1% | |
| 30. Juni 2026 | $-0.05 | $-0.05 | 2.0% | |
| 31. März 2026 | $-0.02 | $0.09 | -121.8% | |
| 31. Dezember 2025 | $0.02 | $0.01 | 96.1% | |
| 30. September 2025 | $0.02 | $-0.01 | 296.1% | |
| 30. Juni 2025 | $-0.07 | $-0.20 | 65.7% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Cost of Revenue | $31M | $28M | $29M | $30M | $24M | $21M | $17M | · | · | |
| R&D Expense | $9M | $7M | $10M | $12M | $9M | $7M | $6M | $5M | $4M | |
| SG&A Expense | $11M | $9M | $11M | $10M | $9M | $7M | $7M | $5M | $4M | |
| Operating Expenses | · | · | · | · | · | · | $34M | $27M | $22M | |
| Operating Income | $-1M | $5M | $-7M | $-5M | $607.0K | $366.0K | $-2M | $270.0K | $-1M | |
| Other Non-op | $211.0K | $73.0K | $48.0K | $-11.0K | $-24.0K | $71.0K | $-42.0K | $-39.0K | $-89.0K | |
| Pretax Income | $-929.0K | $5M | $-7M | $-5M | $583.0K | $437.0K | $-2M | $231.0K | $-1M | |
| Income Tax | $246.0K | $-75.0K | $-32.0K | $68.0K | $35.0K | $75.0K | $130.0K | $103.0K | $33.0K | |
| Net Income | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| EPS (Basic) | $-0.08 | $0.34 | $-0.54 | $-0.39 | $0.04 | $0.03 | $-0.18 | $0.01 | $-0.13 | |
| EPS (Diluted) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 | |
| Shares (Basic) | 13,832,385 | 13,659,786 | 13,547,604 | 13,541,559 | 13,197,170 | 13,138,995 | 11,843,463 | 11,340,184 | 10,991,105 | |
| Shares (Diluted) | 13,832,385 | 14,266,781 | 13,547,604 | 13,541,559 | 14,159,799 | 14,573,561 | 11,843,463 | 14,096,117 | 10,991,105 | |
| EBITDA | $260.0K | $6M | $-6M | $-3M | $2M | $2M | $-978.0K | $876.0K | $-994.0K |
Bilanz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $10M | $3M | $10M | $9M | $5M | $8M | $3M | $856.0K | |
| Receivables | $13M | $11M | $10M | $8M | $10M | $7M | $5M | $4M | $4M | |
| Prepaid Expense | $1M | $1M | $1M | $1M | $1M | $957.0K | $385.0K | $308.0K | $287.0K | |
| Current Assets | $19M | $22M | $14M | $19M | $20M | $13M | $13M | $8M | $5M | |
| PP&E (Net) | · | · | · | · | $7M | $6M | $4M | $3M | $2M | |
| PP&E (Gross) | $16M | $16M | $16M | $16M | $13M | $10M | $7M | $5M | $4M | |
| Accum. Depreciation | $13M | $12M | $10M | $9M | $6M | $4M | $3M | $2M | $1M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $670.0K | $669.0K | |
| Other Non-current Assets | $212.0K | $196.0K | $185.0K | $15.0K | $15.0K | $15.0K | $128.0K | $128.0K | $116.0K | |
| Total Assets | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Accounts Payable | $7M | $4M | $6M | $5M | $3M | $2M | $3M | $3M | $2M | |
| Accrued Liabilities | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $1M | $569.0K | |
| Current Liabilities | $20M | $24M | $22M | $22M | $17M | $11M | $12M | $8M | $7M | |
| Capital Leases | $3M | $5M | $6M | $7M | $8M | $9M | $3M | $0 | $17.0K | |
| Other Non-current Liabilities | $7.0K | $85.0K | $401.0K | $551.0K | $391.0K | $181.0K | $178.0K | $151.0K | $151.0K | |
| Total Liabilities | $23M | $29M | $28M | $30M | $26M | $20M | $16M | $9M | $8M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $13.0K | $13.0K | $12.0K | $11.0K | |
| Retained Earnings | $-81M | $-80M | $-85M | $-77M | $-72M | $-73M | $-73M | $-71M | $-71M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $74.0K | $0 | · | · | $0 | $1M | |
| Stockholders' Equity | $4M | $4M | $-2M | $5M | $9M | $7M | $5M | $2M | $3.0K | |
| Liabilities + Equity | $27M | $32M | $26M | $34M | $35M | $28M | $21M | $11M | $8M | |
| Shares Outstanding | 13,886,826 | 13,897,503 | 13,714,099 | 13,558,650 | 13,522,441 | 13,414,066 | 12,726,728 | 11,619,538 | 11,003,228 |
Cashflow
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $2M | $925.0K | $825.0K | $606.0K | $360.0K | |
| Stock-based Comp | $1M | $654.0K | $1M | $864.0K | $912.0K | $598.0K | $600.0K | $636.0K | $1M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-6M | $431.0K | $-2M | $6M | $4M | $-4M | $3M | $492.0K | $-1M | |
| Operating Cash Flow | $-4M | $7M | $-6M | $4M | $6M | $-2M | $3M | $2M | $-1M | |
| CapEx | $564.0K | $389.0K | $836.0K | $3M | $2M | $3M | $2M | $834.0K | $1M | |
| Investing Cash Flow | $-540.0K | $-389.0K | $-836.0K | $-3M | $-2M | $-3M | $-2M | $-834.0K | $-1M | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | |
| Stock Repurchased | · | $0 | $634.0K | $74.0K | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | $-634.0K | $-74.0K | · | · | · | · | $0 | |
| Financing Cash Flow | $99.0K | $170.0K | $-527.0K | $11.0K | $207.0K | $1M | $4M | $1M | $13.0K | |
| Net Change in Cash | $-5M | $7M | $-8M | $1M | $4M | $-4M | $5M | $2M | $-2M | |
| Taxes Paid | $242.0K | $43.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | $-5M | $7M | $-7M | $1M | $4M | $-5M | $685.0K | $1M | $-2M |
Rentabilität
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% | 0.89% | · | 1.0% | · | |
| Net Margin | -2.0% | 8.3% | -14.5% | -9.9% | 1.1% | 0.88% | · | 0.47% | · | |
| Pretax Margin | -1.6% | 8.1% | -14.6% | -9.8% | 1.2% | 1.1% | · | 0.85% | · | |
| EBITDA Margin | 0.44% | 10.8% | -11.3% | -5.9% | 4.3% | 3.8% | · | 3.2% | · | |
| ROA | -4.0% | 16.1% | -24.1% | -15.3% | 1.7% | 1.5% | -12.5% | 1.3% | -18.6% | |
| ROE | -30.5% | 211.1% | 367.4% | -91.2% | 6.0% | 4.7% | -36.9% | 5.6% | -744.4% | |
| ROIC | -36.6% | 122.7% | 384.9% | -114.8% | 6.3% | 4.1% | -36.3% | 6.7% | -46165.5% |
Liquidität & Solvenz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 | 1.1 | 1.1 | 1.0 | 0.7 | |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 | 1.0 | 1.1 | 0.9 | 0.6 |
Effizienz
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 2.0 | 1.9 | 1.7 | 1.5 | 1.6 | 1.7 | · | 2.8 | · | |
| Receivables Turnover | 4.9 | 5.5 | 5.8 | 6.3 | 6.0 | 7.0 | · | 6.5 | · |
Pro Aktie
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $0.27 | $-0.14 | $0.34 | $0.67 | $0.55 | $0.42 | $0.19 | $0.00 | |
| Revenue / Share | $4.30 | $3.99 | $3.70 | $3.98 | $3.47 | $2.82 | · | $1.92 | · | |
| Cash Flow / Share | $-0.32 | $0.52 | $-0.45 | $0.29 | $0.46 | $-0.12 | $0.25 | $0.13 | · | |
| Cash / Share | $0.35 | $0.71 | $0.19 | $0.75 | $0.67 | $0.35 | $0.65 | $0.28 | $0.08 | |
| EPS (TTM) | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 |
Wachstumsraten
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.4% | 13.5% | -6.9% | 9.7% | 19.7% | 27.8% | · | · | · | |
| Revenue CAGR 3Y | 3.3% | 5.1% | 6.9% | 18.8% | · | · | · | · | · | |
| Revenue CAGR 5Y | 7.7% | 12.1% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | · | · | 100.0% | · | · | · | · | |
| EPS CAGR 3Y | · | 102.1% | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | · | · | 51.4% | · | · | · | · | |
| Net Income CAGR 3Y | · | 104.7% | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $3M | $20M | |
| Net Income TTM | $-1M | $5M | $-7M | $-5M | $548.0K | $362.0K | $-2M | $128.0K | $-1M | |
| Market Cap | $83M | $99M | $66M | $67M | $104M | $144M | $98M | $106M | $48M | |
| P/E | -74.5 | 21.7 | -9.0 | -12.6 | 192.0 | 536.5 | -42.9 | 908.0 | -33.4 | |
| P/S | 1.4 | 1.7 | 1.3 | 1.2 | 2.1 | 3.5 | 3.1 | 36.4 | 2.4 | |
| P/B | 21.0 | 26.1 | -34.6 | 14.4 | 11.4 | 19.4 | 18.5 | 47.1 | 15918.0 | |
| P / Tangible Book | 23.0 | 28.7 | · | 15.5 | 11.9 | 20.3 | 20.6 | · | · | |
| P / Cash Flow | -18.5 | 13.3 | -10.7 | 16.8 | 16.0 | -85.6 | 33.8 | 56.7 | -39.0 | |
| P / FCF | -16.4 | 14.1 | -9.4 | 60.6 | 25.2 | -29.0 | 143.4 | 102.6 | -19.5 | |
| Earnings Yield | -1.3% | 4.6% | -11.1% | -7.9% | 0.52% | 0.19% | -2.3% | 0.11% | -3.0% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15M | $14M | $17M | $15M | $14M | $12M | $17M | $13M | $14M | $14M | $12M | $12M | $13M | $13M | $13M | $14M | |
| Cost of Revenue | $8M | $7M | $9M | $7M | $8M | $7M | $7M | $7M | $7M | $7M | $8M | $7M | $8M | $7M | $8M | $7M | |
| R&D Expense | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $1M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Operating Income | $-409.0K | $-522.0K | $-276.0K | $185.0K | $-527.0K | $-2M | $4M | $732.0K | $1M | $-272.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $7.0K | |
| Other Non-op | $-6.0K | $27.0K | $39.0K | $70.0K | $75.0K | $42.0K | $19.0K | $7.0K | $5.0K | $81.0K | $58.0K | $-105.0K | $14.0K | $-20.0K | $36.0K | $-9.0K | |
| Pretax Income | $-415.0K | $-495.0K | $-237.0K | $255.0K | $-452.0K | $-2M | $5M | $739.0K | $1M | $-191.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-2.0K | |
| Income Tax | $11.0K | $172.0K | $42.0K | $18.0K | $14.0K | $-130.0K | $23.0K | $11.0K | $21.0K | $-82.0K | $11.0K | $11.0K | $28.0K | $20.0K | $17.0K | $14.0K | |
| Net Income | $-426.0K | $-728.0K | $-279.0K | $268.0K | $-466.0K | $-2M | $4M | $728.0K | $1M | $-109.0K | $-3M | $-2M | $-3M | $-3M | $-2M | $-16.0K | |
| EPS (Basic) | $-0.03 | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.14 | $0.33 | $0.05 | $0.10 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | |
| EPS (Diluted) | · | $-0.05 | $-0.02 | $0.02 | $-0.03 | $-0.12 | $0.31 | $0.05 | $0.09 | $-0.01 | $-0.19 | $-0.15 | $-0.19 | $-0.19 | $-0.18 | $0.00 | |
| Shares (Basic) | 13,897,535 | · | 13,886,797 | 13,791,913 | 13,788,414 | · | 13,700,627 | 13,593,766 | 13,593,766 | · | 13,593,758 | 13,497,061 | 13,506,782 | · | 13,558,642 | 13,528,643 | |
| Shares (Diluted) | · | · | 13,886,797 | 14,457,837 | 13,788,414 | · | 14,364,904 | 14,016,953 | 14,042,379 | · | 13,593,758 | 13,497,061 | 13,506,782 | · | 13,558,642 | 13,528,643 | |
| EBITDA | $-95.0K | · | $65.0K | $542.0K | $-169.0K | · | $5M | $1M | $2M | · | $-2M | $-1M | $-2M | · | $-2M | $567.0K |
Bilanz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $5M | $7M | $9M | $10M | $10M | $3M | $3M | $3M | $3M | $4M | $6M | $5M | $10M | $12M | $11M | |
| Receivables | $14M | $13M | $12M | $12M | $9M | $11M | $16M | $10M | $9M | $10M | $8M | $8M | $9M | $8M | $8M | $9M | |
| Prepaid Expense | $1M | $1M | $991.0K | $1M | $1M | $1M | $713.0K | $860.0K | $1M | $1M | $835.0K | $780.0K | $1M | $1M | $661.0K | $834.0K | |
| Current Assets | $19M | $19M | $20M | $21M | $21M | $22M | $20M | $14M | $13M | $14M | $13M | $14M | $15M | $19M | $20M | $21M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $8M | |
| PP&E (Gross) | $17M | $16M | $16M | $16M | $16M | $16M | $17M | $16M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $14M | |
| Accum. Depreciation | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $11M | $11M | $10M | $10M | $9M | $9M | $9M | $7M | $7M | |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | |
| Other Non-current Assets | $201.0K | $212.0K | $196.0K | $196.0K | $196.0K | $196.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $185.0K | $184.0K | $15.0K | $15.0K | $15.0K | |
| Total Assets | $33M | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | |
| Accounts Payable | $6M | $7M | $6M | $6M | $5M | $4M | $5M | $5M | $5M | $6M | $5M | $5M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $3M | $3M | $3M | $2M | $2M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Current Liabilities | $19M | $20M | $21M | $22M | $23M | $24M | $20M | $19M | $19M | $22M | $22M | $21M | $20M | $22M | $21M | $19M | |
| Capital Leases | $10M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | $8M | |
| Other Non-current Liabilities | $215.0K | $7.0K | $27.0K | $46.0K | $66.0K | $85.0K | $285.0K | $324.0K | $363.0K | $401.0K | $439.0K | $476.0K | $514.0K | $551.0K | $588.0K | $624.0K | |
| Total Liabilities | $29M | $23M | $24M | $26M | $27M | $29M | $25M | $25M | $25M | $28M | $29M | $28M | $28M | $30M | $29M | $27M | |
| Common Stock | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Retained Earnings | $-81M | $-81M | $-80M | $-80M | $-80M | $-80M | $-78M | $-83M | $-83M | $-85M | $-84M | $-82M | $-80M | $-77M | $-75M | $-72M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $676.0K | $74.0K | · | · | |
| Stockholders' Equity | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $681.0K | $-332.0K | $-2M | $-2M | $93.0K | $2M | $5M | $7M | $9M | |
| Liabilities + Equity | $33M | $27M | $28M | $30M | $31M | $32M | $31M | $25M | $25M | $26M | $27M | $28M | $30M | $34M | $36M | $36M | |
| Shares Outstanding | 13,918,569 | 13,886,826 | 13,886,826 | 13,886,326 | 13,788,421 | 13,777,170 | 13,705,570 | 13,698,903 | 13,593,766 | 13,593,766 | 13,593,766 | 13,593,766 | 13,484,110 | 13,544,228 | 13,558,650 | 13,558,650 |
Cashflow
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $314.0K | $344.0K | $341.0K | $357.0K | $358.0K | $354.0K | $398.0K | $399.0K | $449.0K | $490.0K | $481.0K | $484.0K | $445.0K | $437.0K | $575.0K | $560.0K | |
| Stock-based Comp | $766.0K | $357.0K | $423.0K | $249.0K | $208.0K | $131.0K | $256.0K | $9.0K | $258.0K | $263.0K | $379.0K | $53.0K | $423.0K | $208.0K | $331.0K | $119.0K | |
| Other Non-cash | $-1M | · | · | · | $470.0K | · | · | · | $-2M | · | · | · | $-2M | · | · | · | |
| Operating Cash Flow | $-492.0K | $-2M | $-1M | $-2M | $600.0K | $7M | $490.0K | $-283.0K | $311.0K | $-2M | $-919.0K | $589.0K | $-4M | $-692.0K | $2M | $3M | |
| CapEx | $55.0K | $239.0K | $37.0K | $242.0K | $46.0K | $253.0K | $42.0K | $94.0K | $0 | $-3.0K | $18.0K | $79.0K | $668.0K | $760.0K | $754.0K | $604.0K | |
| Investing Cash Flow | $-55.0K | $-238.0K | $-14.0K | $-242.0K | $-46.0K | $-253.0K | $-42.0K | $-94.0K | $0 | $3.0K | $-18.0K | $-79.0K | $-668.0K | $-760.0K | $-754.0K | $-604.0K | |
| Stock Repurchased | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $32.0K | $602.0K | $74.0K | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $0 | · | · | · | $-602.0K | · | · | · | |
| Financing Cash Flow | $33.0K | $-19.0K | $-36.0K | $168.0K | $-14.0K | $-32.0K | $0 | $239.0K | $-37.0K | $-37.0K | $-108.0K | $134.0K | $-590.0K | $-75.0K | $0 | $86.0K | |
| Net Change in Cash | $-514.0K | $-2M | $-1M | $-2M | $540.0K | $7M | $448.0K | $-138.0K | $274.0K | $-2M | $-1M | $644.0K | $-5M | $-2M | $819.0K | $3M | |
| Free Cash Flow | $-547.0K | · | · | · | $554.0K | · | · | · | $311.0K | · | · | · | $-5M | · | · | · |
Rentabilität
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2.7% | · | -1.7% | 1.2% | -3.8% | · | 26.4% | 5.4% | 9.4% | · | -21.4% | -16.9% | -20.3% | · | -19.2% | 0.05% | |
| Net Margin | -2.8% | · | -1.7% | 1.8% | -3.1% | · | 26.4% | 5.4% | 9.3% | · | -21.1% | -17.9% | -20.4% | · | -19.1% | -0.11% | |
| Pretax Margin | -2.7% | · | -1.4% | 1.7% | -3.2% | · | 26.5% | 5.5% | 9.5% | · | -21.0% | -17.8% | -20.2% | · | -19.0% | -0.01% | |
| EBITDA Margin | -0.62% | · | 0.39% | 3.6% | -1.2% | · | 28.7% | 8.4% | 12.6% | · | -17.4% | -12.7% | -16.8% | · | -14.7% | 4.0% | |
| ROA | -1.3% | · | -0.94% | 0.97% | -1.6% | · | 15.7% | 2.7% | 4.8% | · | -8.0% | -6.4% | -8.0% | · | -7.0% | -0.05% | |
| ROE | -11.5% | · | -5.7% | 11.1% | -27.5% | · | 263.6% | 188.1% | 167.2% | · | -101.1% | -44.7% | -47.1% | · | -29.9% | -0.19% | |
| ROIC | -10.8% | · | -7.6% | 4.1% | -15.5% | · | 81.8% | 105.9% | -394.0% | · | 125.8% | -2113.4% | -135.6% | · | -35.0% | 0.61% |
Liquidität & Solvenz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | · | 1.0 | 1.0 | 0.9 | · | 1.0 | 0.7 | 0.7 | · | 0.6 | 0.7 | 0.7 | · | 1.0 | 1.1 | |
| Quick Ratio | 1.0 | · | 0.9 | 0.9 | 0.9 | · | 1.0 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.7 | · | 0.9 | 1.1 |
Effizienz
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | |
| Receivables Turnover | 1.3 | · | 1.2 | 1.4 | 1.5 | · | 1.4 | 1.5 | 1.6 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.7 |
Pro Aktie
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | · | $0.31 | $0.30 | $0.25 | · | $0.40 | $0.05 | $-0.02 | · | $-0.15 | $0.01 | $0.14 | · | $0.52 | $0.68 | |
| Revenue / Share | · | · | $1.19 | $1.04 | $1.01 | · | $1.19 | $0.96 | $1.00 | · | $0.88 | $0.86 | $0.93 | · | $0.94 | $1.06 | |
| Cash Flow / Share | · | · | · | · | $0.04 | · | · | · | $0.02 | · | · | · | $-0.30 | · | · | · | |
| Cash / Share | $0.31 | · | $0.51 | $0.61 | $0.75 | · | $0.23 | $0.20 | $0.21 | · | $0.33 | $0.41 | $0.36 | · | $0.86 | $0.80 | |
| EPS (TTM) | $-0.08 | · | $-0.15 | $0.18 | $0.21 | · | $0.44 | $-0.06 | $-0.26 | · | $-0.72 | $-0.71 | $-0.56 | · | $-0.22 | $0.01 |
Bewertung (TTM)
| Kennzahl | Trend | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $61M | · | $58M | $58M | $57M | · | $59M | $54M | $52M | · | $49M | $50M | $53M | · | $54M | $54M | |
| Net Income TTM | $-1M | · | $-2M | $2M | $3M | · | $6M | $-598.0K | $-3M | · | $-10M | $-10M | $-8M | · | $-3M | $108.0K | |
| Market Cap | $75M | · | $102M | $95M | $87M | · | $151M | $54M | $65M | · | $79M | $74M | $88M | · | $56M | $94M | |
| P/E | -67.0 | · | -48.7 | 37.9 | 30.1 | · | 25.0 | -65.2 | -18.4 | · | -8.1 | -7.7 | -11.6 | · | -18.7 | 694.0 | |
| P/S | 1.2 | · | 1.8 | 1.6 | 1.5 | · | 2.6 | 1.0 | 1.3 | · | 1.6 | 1.5 | 1.7 | · | 1.0 | 1.7 | |
| P/B | 19.2 | · | 23.7 | 22.7 | 24.8 | · | 27.5 | 78.7 | -196.1 | · | -38.4 | 798.1 | 46.1 | · | 7.9 | 10.3 | |
| P / Tangible Book | 21.0 | · | 25.7 | 24.7 | 27.5 | · | 29.3 | 154.8 | · | · | · | · | 55.9 | · | 8.3 | 10.6 | |
| P / Cash Flow | -151.6 | · | · | · | 145.2 | · | · | · | 209.4 | · | · | · | -22.0 | · | · | · | |
| Earnings Yield | -1.5% | · | -2.1% | 2.6% | 3.3% | · | 4.0% | -1.5% | -5.4% | · | -12.4% | -13.0% | -8.6% | · | -5.3% | 0.14% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Umsatz | $59M | $57M | $50M | $54M | $49M |
| Betriebsgewinnmarge % | -1.9% | 8.0% | -14.7% | -9.8% | 1.2% |
| Nettoergebnis | $-1M | $5M | $-7M | $-5M | $548.0K |
| Verwässerte EPS | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 |
| Kennzahl | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 1.0 | 0.9 | 0.6 | 0.9 | 1.1 |
| Quick Ratio | 0.9 | 0.9 | 0.6 | 0.8 | 1.1 |
| Kennzahl | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Freier Cashflow | $-5M | $7M | $-7M | $1M | $4M |
Institutionelle Eigentümer (13F) 29 Einreicher · $38.4M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 4 (0 vs. Vorquartal) | 2 (-3 vs. Vorquartal) | 5 (0 vs. Vorquartal) | 7 (0 vs. Vorquartal) | +134K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BATTERY MANAGEMENT CORP. | $14.917.506 | 2.421.673 | 38,86% | Aktien |
| NEA Management Company, LLC | $10.556.515 | 1.713.720 | 27,50% | Aktien |
| VANGUARD GROUP INC | $2.312.121 | 334.605 | 6,02% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.856.334 | 301.353 | 4,84% | Aktien |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $1.821.253 | 295.658 | 4,74% | Aktien |
| MORGAN STANLEY | $1.450.064 | 235.400 | 3,78% | Aktien |
| BANK OF AMERICA CORP /DE/ | $1.318.597 | 214.058 | 3,43% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $856.480 | 139.039 | 2,23% | Aktien |
| BlackRock, Inc. | $799.864 | 129.848 | 2,08% | Aktien |
| Mink Brook Asset Management LLC | $685.842 | 111.338 | 1,79% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $470.118 | 76.300 | 1,22% | Aktien |
| HighTower Advisors, LLC | $258.110 | 41.901 | 0,67% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $204.752 | 33.239 | 0,53% | Aktien |
| NORTHERN TRUST CORP | $171.926 | 27.910 | 0,45% | Aktien |
| STATE STREET CORP | $161.410 | 26.203 | 0,42% | Aktien |
| Bank of New York Mellon Corp | $133.142 | 21.614 | 0,35% | Aktien |
| CITADEL ADVISORS LLC | $112.697 | 18.295 | 0,29% | Aktien |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $112.241 | 18.221 | 0,29% | Aktien |
| Mesirow Financial Investment Management, Inc. | $97.328 | 15.800 | 0,25% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $78.694 | 12.775 | 0,20% | Aktien |
| Vanguard Global Advisers, LLC | $12.893 | 2.093 | 0,03% | Aktien |
| ACADIAN ASSET MANAGEMENT LLC | $125 | 20.523 | 0,00% | Aktien |
| BARCLAYS PLC | $80 | 13 | 0,00% | Aktien |
| Cambridge Investment Research Advisors, Inc. | $75 | 12.252 | 0,00% | Aktien |
| JPMORGAN CHASE & CO | $71 | 11 | 0,00% | Aktien |
| Cassaday & Co Wealth Management LLC | $62 | 10 | 0,00% | Aktien |
| SBI Securities Co., Ltd. | $25 | 4 | 0,00% | Aktien |
| FMR LLC | $5 | 1 | 0,00% | Aktien |
| Capital Advisors, Ltd. LLC | $0 | 48 | 0,00% | Aktien |
Aktivisten & 5%+-Eigentümer 9 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| New Enterprise Associates 14, L.P., NEA Partners 14, L.P., NEA 14 GP, LTD, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Mohamad Makhzoumi, Scott D. Sandell ×2 Einreichungen | 6. Mai 2024 | · | Erste Einreichung | · | SEC |
| Norman H. Pessin, Brian Pessin ×2 Einreichungen | 8. August 2017 | · | Erste Einreichung | Passive Anlage | SEC |
| PAR Investment Partners, L.P., PAR Group, L.P., PAR Capital Management, Inc., Arthur G. Epker, III ×4 Einreichungen | 28. Oktober 2016 | · | Erste Einreichung | · | SEC |
| Joel Ackerman ×2 Einreichungen | 23. März 2015 | · | Erste Einreichung | Passive Anlage | SEC |
| Ronnie Morris ×2 Einreichungen | 23. März 2015 | · | Erste Einreichung | Passive Anlage | SEC |
| Battery Ventures IX, L.P., Battery Investment Partners IX, LLC, Battery Partners IX, LLC, Battery Management Corp., Scott R. Tobin, Thomas J. Crotty, Richard D. Frisbie, Kenneth P Lawler, R. David Tabors, Roger H. Lee, Neeraj Agrawal, Michael M. Brown, Jesse Feldman ×4 Einreichungen | 16. März 2015 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 29. Mai 2007 | · | Erste Einreichung | · | SEC |
| Manuel Hidalgo. | 18. Januar 2007 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 11. Januar 2007 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 18 Insider · 7 Führungskräfte · 11 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Robert Lawrence Brainin | CEO | 16. Juli 2025 A | · | 0 | 0 | $0 |
| Ronnie Morris | CEO | 17. März 2023 P | 858.878 | 0 | 0 | $0 |
| CHAMPIONS SPORTS INC | Chairman, President and CEO | 11. Oktober 2004 P | 9.548.000 | 0 | 0 | $0 |
| Mark Schonau | Accting PEO and CFO | 21. Juli 2010 A | 8.526 | 0 | 0 | $0 |
| Brady Davis | President | 9. Oktober 2023 A | · | 0 | 0 | $0 |
| Douglas D Burkett | President | 3. Oktober 2008 P | · | 0 | 0 | $0 |
| David Barry Miller | Vice President, Finance | 21. Juli 2016 D | · | 0 | 0 | $0 |
| Philip P. Breitfeld | Direktor | 5. November 2025 A | 5.717 | 0 | 0 | $0 |
| Daniel Newman Mendelson | Direktor | 5. November 2025 A | 198.625 | 0 | 0 | $0 |
| David Sidransky | Direktor | 5. November 2025 A | 767.043 | 0 | 0 | $0 |
| Joel Ackerman | Direktor | 5. November 2025 A | 1.056.539 | 0 | 0 | $0 |
| Scott R. Tobin | Direktor | 5. November 2025 A | 30.000 | 0 | 0 | $0 |
| Abba David Poliakoff | Direktor | 19. Januar 2021 M | 81.274 | 0 | 0 | $0 |
| Arthur G Epker III | Direktor | 13. Oktober 2014 A | · | 0 | 0 | $0 |
| Ana Stancic | Direktor | 14. Juli 2011 A | · | 0 | 0 | $0 |
| Michael M. Brown | 10%-Eigentümer | 28. Januar 2013 A | 16.031.040 | 0 | 0 | $0 |
| James Martell | · | 6. Januar 2012 G | 1.784.828 | 0 | 0 | $0 |
| Durwood Settles | · | 15. Januar 2007 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 3 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
CSBR Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| CSBR | $83M | -74.5 | 4.4% | -2.0% | -30.5% | · |
| NAUT | $247M | -4.1 | · | · | -34.9% | · |
| QTRX | $297M | -2.5 | 1.1% | -77.1% | -36.4% | 46.8% |
| CDXS | $147M | -3.3 | 18.6% | -62.5% | -82.8% | · |
| SEER | · | -1.4 | 17.0% | · | · | · |
| MXCT | $166M | -3.7 | -14.5% | -135.1% | -24.6% | 81.2% |
| HYFT | · | · | · | -89.7% | -78.9% | 58.8% |
| CIRC | · | · | · | · | · | · |
| RPID | · | -2.8 | 19.7% | -140.3% | -107.4% | · |
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | · |
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Derzeit kein offenes Signal – keine Karte ist ausgefüllt, und das ist ehrlich.
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.